Serratus Plane Block (SPB) Versus Capsaïcine Versus Botox-A for Chronic Neuropathic Pain in Post-mastectomy Syndrome

Recruiting now · Phase 2

Conditions studied: Post-Mastectomy Neuropathic Pain Syndrome

In brief

The goal of this phase II clinical trial is to study the effectiveness of a treatment with Serratus Plane Block (SPB) or Botox-A in comparison with capsaicin for the control of chronic neuropathic pain of post-mastectomy syndrom, that is not adequately managed by systemic treatment alone. The primary outcome will be the pain evaluation at 8 weeks. 123 patients with chronic neuropathic pain of post-mastectomy syndrom insufficiently relieved by systemic treatment alone will be recruited over 24 months at the Centre Oscar Lambret. Patients will be randomly assigned to one of three treatment groups (41 patients per group): Capsaicin Botulinum toxin A SPB Patients will be followed for 24 weeks after the study treatment. The follow-up will include remote evaluation and 2 medical visits during which pain and quality of life will be assessed.

Key facts

Study ID

NCT06807164

Run by

Centre Oscar Lambret

People needed

123

Starts

2026-03-31

Expected to finish

2027-12-30

Last updated by the study team

2026-03-27

Who can join

Age: 18 and older. Sex: female. Healthy volunteers: not accepted.

You may qualify if…

• Women aged ≥ 18 years;
• Unilateral breast cancer treated by total or partial mastectomy:
• with sentinel lymph node technique (SLN) or axillary dissection;
• with or without immediate reconstruction using a prosthesis;
• associated or not with radiotherapy and/or chemotherapy;
• Presenting moderate to severe chronic neuropathic pain, defined by:
• Numerical Pain Scale (NPS) ≥ 3 and DN4 ≥ 4,
• on a localised aera ((≤ 240 cm²), at the surgical site, in the axillary hollow, or on the inner side of the ipsilateral arm,
• between 3 and 9 months after breast surgery,
• with indication of additional locoregional treatment in complement to a systemic treatment of chronic neuropathic pain, as recommended by the SFETD - French Society for the Study and Treatment of Pain (tricyclic antidepressants or IRSNA or gabapentinoid PLUS lidocaine patch, at the appropriate dosage) and implemented for at least 4 weeks;
• Patient affiliated with a health insurance plan;
• Patient informed and having consented to participate in the trial.

You may not qualify if…

• Ipsilateral breast cancer recurrence, regardless of the first treatment;
• History of breast or thoracic surgery prior to mastectomy with residual pain;
• Painful polyneuropathy related to chemotherapy requiring treatment;
• Ongoing or planned loco-regional adjuvant radiotherapy within the next 8 weeks;
• Treatment area not suitable for potential botulinum toxin type A treatment;
• Breast reconstruction using flap or lipomodelling;
• Indication for breast reconstruction within the next 8 weeks;
• Chronic pain of another etiology such as:
• Neuropathic pain secondary to a neuroma (localized pain),
• Radiodermatitis,
• Phantom breast pain,
• Lymphedema,
• Complex regional pain syndrome,
• Adhesive capsulitis,
• Fibromyalgia;
• Hypersensitivity or allergy to anesthetics, capsaicin, naropein, clonidine hydrochloride, an amide-type local anesthetic, botulinum toxin type A, or any excipient contained in the preparations;
• Infection or inflammation at the injection site;
• Therapeutic/effective anticoagulation;
• Clinical signs or medical history leading to the diagnosis of:
• Hemostasis disorder,
• Local infection,
• Severe renal insufficiency (creatinine clearance < 30 mL/min),
• Thrombocytopenia < 50,000 platelets/mm3;
• Generalized muscle activity disorders (e.g., myasthenia, Lambert-Eaton syndrome);
• Heart rate lower than 60/minute;

Where it is running

• Centre Oscar Lambret — Lille, Hauts-de-France, France (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.